# US 2021/0069249 A1 · Methods and compositions of cytotoxic t cell depletion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069249 A1
- Document ID: US20210069249A1
- Status: Published application
- Kind: A1
- Application number: 17/050,698
- Filed: 2019-04-26
- Published: 2021-03-11
- Earliest claimed: 2018-04-27
- Assignees: Crispr Therapeutics AG; Bayer HealthCare LLC
- Applicants: Crispr Therapeutics AG; Bayer Healthcare, LLC
- Inventors: Basha STANKOVICH
- Web page: https://patentgrep.com/patent/US20210069249A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/421: {Immunoglobulin superfamily}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/7155: {for interleukins [IL]}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12N 15/907: {in mammalian cells}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/30: Special therapeutic applications
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present application relates to compositions and methods for controlled cytotoxic T cell depletion, such as for the treatment of various diseases and conditions associated with cytotoxic T cells. The application provides engineered T cells comprising inter alia nucleic acids encoding an anti-cytotoxic T lymphocyte (CTL) protein capable of conferring to the engineered T cell cytotoxicity towards a CTL. The anti-CTL protein may comprise an extracellular BETA2-microglobulin domain.

## Claims

### Claim 1

An engineered T cell comprising
a) an endogenous T cell receptor alpha (TRA) gene modified to encode a non-functional T cell receptor alpha constant (TRAC) domain; and
b) nucleic acid encoding an anti-cytotoxic T lymphocyte (CTL) protein capable of conferring to the engineered T cell cytotoxicity towards a CTL that is reactive towards the engineered T cell.

### Claim 2 (depends on 1)

The cell of claim 1, wherein the anti-CTL protein comprises an extracellular β2-microglobulin domain, a transmembrane domain, a co-stimulatory domain, and a cytoplasmic signaling domain.

### Claim 3 (depends on 2)

The cell of claim 2, wherein the extracellular β2-microglobulin domain comprises the amino acid sequence of SEQ ID NO: 49 or a variant thereof comprising at least 85% homology to SEQ ID NO: 49.

### Claim 4 (depends on 3)

The cell of claim 3, wherein the anti-CTL protein transmembrane domain comprises a CD8 transmembrane domain, the anti-CTL protein co-stimulatory domain comprises a 4-1BB co-stimulatory domain, and/or the anti-CTL protein cytoplasmic signaling domain comprises a CD3-ζ cytoplasmic signaling domain.

### Claim 5 (depends on 3, 4)

The cell of claim 3 or 4, wherein i) the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 50 or a variant thereof having at least 85% homology to SEQ ID NO: 50; ii) the 4-1BB co-stimulatory domain comprises the amino acid sequence of SEQ ID NO: 51 or a variant thereof having at least 85% homology to SEQ ID NO: 51; and/or iii) the CD3-ζ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 52 or a variant thereof having at least 85% homology to SEQ ID NO: 52.

### Claim 6 (depends on 2, 3, 4, 5)

The cell of any one of claims 2-5, wherein the anti-CTL protein comprises the amino acid sequence of SEQ ID NO: 53 or a variant thereof having at least 85% homology to SEQ ID NO: 53.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The cell of any one of claims 1-6, wherein the b) nucleic acid encoding an anti-CTL protein is inserted into the region of the endogenous TIM gene encoding the TRAC domain or the b) nucleic acid encoding an anti-CTL protein is inserted into an endogenous IL2RG gene.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The cell of any one of claims 1-7, further comprising c) one or more nucleic acids encoding polypeptide components of a dimerization activatable chemically induced signaling complex (CISC), wherein the polypeptide components of the CISC comprise
i) a first CISC component comprising a first extracellular binding domain or portion thereof, a hinge domain, a transmembrane domain, and a signaling domain or portion thereof; and
ii) a second CISC component comprising a second extracellular binding domain or portion thereof, a hinge domain, a transmembrane domain, and a signaling domain or portion thereof;
wherein the first CISC component and the second CISC component are configured such that when expressed, they dimerize in the presence of the ligand to create a signaling-competent CISC.

### Claim 9 (depends on 8)

The cell of claim 8, wherein the signaling domain of the first CISC component comprises an IL-2 receptor subunit gamma (IL2Rγ) cytoplasmic signaling domain.

### Claim 10 (depends on 9)

The cell of claim 9, wherein the IL2Rγ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 44 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 44.

### Claim 11 (depends on 8, 9, 10)

The cell of any one of claims 8-10, wherein the first extracellular binding domain or portion thereof comprises an FK506 binding protein (FKBP) domain or a portion thereof.

### Claim 12 (depends on 11)

The cell of claim 11, wherein the FKBP domain comprises the amino acid sequence of SEQ ID NO: 41 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 41.

### Claim 13 (depends on 8, 9, 10, 11, 12)

The cell of any one of claims 8-12, wherein the signaling domain of the second CISC component comprises an IL-2 receptor subunit beta (IL2Rβ) cytoplasmic signaling domain.

### Claim 14 (depends on 13)

The cell of claim 13, wherein the IL2Rβ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 45 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 45.

### Claim 15 (depends on 8, 9, 10, 11, 12, 13, 14)

The cell of any one of claims 8-14, wherein the second extracellular binding domain or portion thereof comprises an FKBP rapamycin binding (FRB) domain or a portion thereof.

### Claim 16 (depends on 15)

The cell of claim 15, wherein the FRB comprises the amino acid sequence of SEQ ID NO: 42 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 42.

### Claim 17 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16)

The cell of any one of claims 8-16, wherein the transmembrane domain of the first and second CISC components comprises, independently, an IL-2 receptor transmembrane domain.

### Claim 18 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The cell of any one of claims 8-17, wherein 1) the one or more nucleic acids encoding the first CISC component are inserted into an endogenous IL2RG gene and the one or more nucleic acids encoding the second CISC component are inserted into the region of the endogenous TRA gene encoding the TRAC domain; or 2) the one or more nucleic acids encoding the first CISC component are inserted into the region of the endogenous TRA gene encoding the TRAC domain and the one or more nucleic acids encoding the second CISC component are inserted into the endogenous IL2RG gene.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The cell of any one of claims 1-18, wherein the ligand is rapamycin or a rapamycin analog (rapalog).

### Claim 20 (depends on 19)

The cell of claim 19, wherein the rapalog is selected from the group consisting of everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, AP21967, sodium mycophenolic acid, benidipine hydrochloride, AP1903, or AP23573, or metabolites, derivatives, and/or combinations thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The cell of any one of claims 1-20, wherein the ligand is present or provided in an amount from 0.05 nM to 500 nM.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The cell of any one of claims 1-25, further comprising g) a nucleic acid encoding a selectable marker.

### Claim 27 (depends on 26)

The cell of claim 26, wherein the selectable marker is a truncated low-affinity nerve growth factor receptor (tLNGFR) polypeptide.

### Claim 28 (depends on 27)

The cell of claim 27, wherein the tLNGFR polypeptide comprises the amino acid sequence of SEQ ID NO: 54.

### Claim 29 (depends on 26, 27, 28)

The cell of any one of claims 26-28, wherein the nucleic acid encoding the selectable marker is inserted into the region of the endogenous TRA gene encoding the TRAC domain or the nucleic acid encoding the selectable marker is inserted into an endogenous IL2RG gene.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The cell of any one of claims 1-29, further comprising e) a nucleic acid encoding a polypeptide that confers resistance to one or more calcineurin inhibitors.

### Claim 31 (depends on 30)

The cell of claim 30, wherein the polypeptide that confers resistance to one or more calcineurin inhibitors confers resistance to tacrolimus (FK506) and/or cyclosporin A (CsA).

### Claim 32 (depends on 30, 31)

The cell of claim 30 or 31, wherein the polypeptide that confers resistance to one or more calcineurin inhibitors is a mutant calcineurin (CN) polypeptide.

### Claim 33 (depends on 32)

The cell of claim 32, wherein the mutant CN polypeptide confers resistance to tacrolimus (FK506) and cyclosporin A (CsA).

### Claim 34 (depends on 32, 33)

The cell of claim 32 or 33, wherein the mutant CN polypeptide is CNb30 (SEQ ID NO: 55).

### Claim 35 (depends on 30, 31, 32, 33, 34)

The cell of any one of claims 30-34, wherein the nucleic acid encoding the polypeptide that confers resistance to one or more calcineurin inhibitors is inserted into the region of the endogenous TRA gene encoding the TRAC domain or the nucleic acid encoding the polypeptide that confers resistance to one or more calcineurin inhibitors is inserted into an endogenous IL2RG gene.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The cell of any one of claims 1-35, further comprising f) a nucleic acid encoding a FKBP-rapamycin binding (FRB) domain polypeptide of the mammalian target of rapamycin (mTOR) kinase.

### Claim 37 (depends on 36)

The cell of claim 36, wherein the FRB domain polypeptide is expressed intracellularly.

### Claim 38 (depends on 36, 37)

The cell of claim 36 or 37, wherein the FRB domain polypeptide comprises the amino acid sequence of SEQ ID NO: 56 or 57 or a variant having at least 90% sequence homology to the amino acid sequence of SEQ ID NO: 56 or 57.

### Claim 39 (depends on 36, 37, 38)

The cell of any one of claims 36-38, wherein the nucleic acid encoding the FRB domain polypeptide is inserted into the region of the endogenous TRA gene encoding the TRAC domain or the nucleic acid encoding the FRB domain polypeptide is inserted into an endogenous IL2RG gene.

### Claim 40

A guide RNA (gRNA) comprising a sequence that is complementary to a sequence in an endogenous TRA gene within or near a region encoding the TRAC domain.

### Claim 41 (depends on 40)

The gRNA of claim 40, wherein the gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 1-3, or a variant thereof having at least 85% homology to any one of SEQ ID NOs: 1-3.

### Claim 42

A guide RNA (gRNA) comprising a sequence that is complementary to a sequence within or near an endogenous IL2RG gene.

### Claim 43 (depends on 42)

The gRNA of claim 42, wherein the gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18, or a variant thereof having at least 85% homology to any one of SEQ ID NOs: 4-18.

### Claim 44 (depends on 40, 41, 42, 43)

A system comprising a) a first gRNA and/or a second gRNA, wherein the first gRNA is the gRNA of claim 40 or 41 and the second gRNA is the gRNA of claim 42 or 43; and b) an RNA-guided endonuclease (RGEN) or a nucleic acid encoding the RGEN.

### Claim 45 (depends on 44)

The system of claim 44, further comprising c) one or more donor templates comprising nucleic acid encoding:
i) an anti-CTL protein;
ii) a first CISC component comprising a first extracellular binding domain or portion thereof, a hinge domain, a transmembrane domain, and a signaling domain or portion thereof or functional derivative thereof; and
iii) a second CISC component comprising a second extracellular binding domain or portion thereof, a hinge domain, a transmembrane domain, and a signaling domain or portion thereof,
wherein the first CISC component and the second CISC component are configured such that when expressed by a T cell, they dimerize in the presence of a ligand to create a signaling competent CISC capable of promoting the survival and/or proliferation of the T cell.

### Claim 46 (depends on 45)

The system of claim 45, wherein the anti-CTL protein comprises an extracellular β2-microglobulin domain, a transmembrane domain, a co-stimulatory domain, and a cytoplasmic signaling domain.

### Claim 47 (depends on 46)

The system of claim 46, wherein the extracellular β2-microglobulin domain comprises the amino acid sequence of SEQ ID NO: 49 or a variant thereof comprising at least 85% homology to SEQ ID NO: 49.

### Claim 48 (depends on 47)

The system of claim 47, wherein the anti-CTL protein transmembrane domain comprises a CD8 transmembrane domain, the anti-CTL protein co-stimulatory domain comprises a 4-1BB co-stimulatory domain, and/or the anti-CTL protein cytoplasmic signaling domain comprises a CD3-ζ cytoplasmic signaling domain.

### Claim 49 (depends on 47, 48)

The system of claim 47 or 48, wherein i) the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 50 or a variant thereof having at least 85% homology to SEQ ID NO: 50; ii) the 4-1BB co-stimulatory domain comprises the amino acid sequence of SEQ ID NO: 51 or a variant thereof having at least 85% homology to SEQ ID NO: 51; and/or iii) the CD3-ζ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 52 or a variant thereof having at least 85% homology to SEQ ID NO: 52.

### Claim 50 (depends on 46, 47, 48, 49)

The system of any one of claims 46-49, wherein the anti-CTL protein comprises the amino acid sequence of SEQ ID NO: 53 or a variant thereof having at least 85% homology to SEQ ID NO: 53.

### Claim 51 (depends on 45, 46, 47, 48, 49, 50)

The system of any one of claims 45-50, wherein the signaling domain of the first CISC component comprises an IL-2 receptor subunit gamma (IL2Rγ) domain.

### Claim 52 (depends on 51)

The system of claim 51, wherein the IL2Rγ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 44 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 44.

### Claim 53 (depends on 45, 46, 47, 48, 49, 50, 51, 52)

The system of any one of claims 45-52, wherein the first extracellular binding domain or portion thereof comprises an FK506 binding protein (FKBP) domain or a portion thereof.

### Claim 54 (depends on 53)

The system of claim 53, wherein the FKBP domain comprises the amino acid sequence of SEQ ID NO: 41 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 41.

### Claim 55 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The system of any one of claims 45-54, wherein the signaling domain of the second CISC component comprises an IL-2 receptor subunit beta (IL2Rβ) domain.

### Claim 56 (depends on 55)

The system of claim 55, wherein the IL2Rβ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 45 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 45.

### Claim 57 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The system of any one of claims 45-56, wherein the second extracellular binding domain or portion thereof comprises an FKBP rapamycin binding (FRB) domain or a portion thereof.

### Claim 58 (depends on 57)

The system of claim 57, wherein the FRB comprises the amino acid sequence of SEQ ID NO: 42 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 42.

### Claim 59 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The system of any one of claims 45-58, wherein the transmembrane domain of the first and second CISC components comprises, independently, an IL-2 receptor transmembrane domain.

### Claim 60 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The system of any one of claims 45-59, wherein the ligand is rapamycin or a rapalog.

### Claim 61 (depends on 60)

The system of claim 60, wherein the rapalog is selected from the group consisting of everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, AP21967, sodium mycophenolic acid, benidipine hydrochloride, AP1903, or AP23573, or metabolites, derivatives, and/or combinations thereof.

### Claim 62 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The system of any one of claims 45-61, wherein the c) one or more donor templates further comprise nucleic acid encoding one or more of:
iv) a selectable marker;
v) a polypeptide that confers resistance to one or more calcineurin inhibitors; or
vi) an FKBP-rapamycin binding (FRB) domain polypeptide of the mammalian target of rapamycin (mTOR) kinase.

### Claim 65 (depends on 62, 63, 64)

The system of any one of claims 62-64, wherein the selectable marker is a truncated low-affinity nerve growth factor receptor (tLNGFR) polypeptide.

### Claim 66 (depends on 65)

The system of claim 65, wherein the tLNGFR polypeptide comprises the amino acid sequence of SEQ ID NO: 54.

### Claim 67 (depends on 62, 63, 64, 65, 66)

The system of any one of claims 62-66, wherein the polypeptide that confers resistance to one or more calcineurin inhibitors is a mutant calcineurin (CN) polypeptide.

### Claim 68 (depends on 67)

The system of claim 67, wherein the mutant CN polypeptide is CNb30 (SEQ ID NO: 55).

### Claim 69 (depends on 62, 63, 64, 65, 66, 67, 68)

The system of any one of claims 62-68, wherein the FRB domain polypeptide comprises the amino acid sequence of SEQ ID NO: 56 or 57 or a variant having at least 90% sequence homology to the amino acid sequence of SEQ ID NO: 56 or 57.

### Claim 70 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The system of any one of claims 44-69, wherein the RGEN is selected from the group consisting of a Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cash, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cpf1 endonuclease, or a functional derivative thereof.

### Claim 71 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The system of any one of claims 44-70, wherein the RGEN is Cas9.

### Claim 72 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The system of any one of claims 44-71, wherein the nucleic acid encoding the RGEN is a ribonucleic acid (RNA) sequence.

### Claim 73 (depends on 72)

The system of claim 72, wherein the RNA sequence encoding the RGEN is linked to the first gRNA or the second gRNA via a covalent bond.

### Claim 74 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The system of any one of claims 45-73, comprising an Adeno-Associated Virus (AAV) vector comprising one of the one or more donor templates.

### Claim 75 (depends on 74)

The system of claim 74, wherein the AAV vector comprises the polynucleotide sequence of any one of SEQ ID NOs: 19-40 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 19-40.

### Claim 76 (depends on 74, 75)

The system of claim 74 or 75, comprising the first gRNA and a first AAV vector and the second gRNA and a second AAV vector, wherein
(A) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 1 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 1, the first AAV vector comprises the polynucleotide sequence of SEQ ID NO: 37 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 37, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 4-18, and the second AAV vector comprises the polynucleotide sequence of SEQ ID NO: 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 40;
(B) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 2 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 2, the first AAV vector comprises the polynucleotide sequence of SEQ ID NO: 38 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 38, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 4-18, and the second AAV vector comprises the polynucleotide sequence of SEQ ID NO: 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 40; or
(C) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 3 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 3, the first AAV vector comprises the polynucleotide sequence of SEQ ID NO: 39 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 39, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 4-18, and the second AAV vector comprises the polynucleotide sequence of SEQ ID NO: 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 40.

### Claim 77 (depends on 74, 75)

The system of claim 74 or 75, comprising the first gRNA and a first AAV vector, wherein
(A) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 1 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 1 and the first AAV vector comprises the polynucleotide sequence of SEQ ID NO: 19 or 22 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 19 or 22;
(B) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 2 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 2 and the first AAV vector comprises the polynucleotide sequence of SEQ ID NO: 20 or 23 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 20 or 23; or
(C) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 3 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 3 and the first AAV vector comprises the polynucleotide sequence of SEQ ID NO: 21 or 24 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 21 or 24.

### Claim 78 (depends on 74, 75)

The system of claim 74 or 75, comprising the first gRNA and a first AAV vector, wherein the first gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18 or a variant thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 4-18 and the first AAV vector comprises the polynucleotide sequence of any one of SEQ ID NOs: 25-36 or a variant thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 25-36.

### Claim 79 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The system of any one of claims 44-78, comprising a ribonucleoprotein (RNP) complex comprising the RGEN and the first gRNA and/or the second gRNA.

### Claim 80 (depends on 79)

The system of claim 79, wherein the RGEN is precomplexed with the first gRNA and/or the second gRNA at a molar ratio of gRNA to RGEN between 1:1 to 20:1, respectively, to form the RNP.

### Claim 81

A vector comprising the nucleic acid sequence of any one of SEQ ID NOs: 19-40, or a variant thereof having at least 85% homology to any one of SEQ ID NOs: 19-40.

### Claim 82 (depends on 81)

The vector of claim 81, wherein the vector is an Adeno Associated Virus (AAV) vector.

### Claim 83 (depends on 40, 41, 42, 43)

A method of editing the genome of a cell, the method comprising providing to the cell:
a) a first gRNA and/or a second gRNA, wherein the first gRNA is the gRNA of claim 40 or 41 and the second gRNA is the gRNA of claim 42 or 43;
b) an RGEN or a nucleic acid encoding the RGEN; and
c) one or more donor templates comprising nucleic acid encoding:
i) an anti-CTL protein;
ii) a first CISC component comprising a first extracellular binding domain or portion thereof, a hinge domain, a transmembrane domain, and a signaling domain or portion thereof or functional derivative thereof; and
iii) a second CISC component comprising a second extracellular binding domain or portion thereof, a hinge domain, a transmembrane domain, and a signaling domain or portion thereof,
wherein the first CISC component and the second CISC component are configured such that when expressed by a T cell, they dimerize in the presence of a ligand to create a signaling competent CISC capable of promoting the survival and/or proliferation of the T cell.

### Claim 84 (depends on 83)

The method of claim 83, wherein the anti-CTL protein comprises an extracellular β2-microglobulin domain, a transmembrane domain, a co-stimulatory domain, and a cytoplasmic signaling domain.

### Claim 85 (depends on 84)

The method of claim 84, wherein the extracellular β2-microglobulin domain comprises the amino acid sequence of SEQ ID NO: 49 or a variant thereof comprising at least 85% homology to SEQ ID NO: 49.

### Claim 86 (depends on 85)

The method of claim 85, wherein the anti-CTL protein transmembrane domain comprises a CD8 transmembrane domain, the anti-CTL protein co-stimulatory domain comprises a 4-1BB co-stimulatory domain, and/or the anti-CTL protein cytoplasmic signaling domain comprises a CD3-ζ cytoplasmic signaling domain.

### Claim 87 (depends on 85, 86)

The method of claim 85 or 86, wherein i) the CD8 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 50 or a variant thereof having at least 85% homology to SEQ ID NO: 50; ii) the 4-1BB co-stimulatory domain comprises the amino acid sequence of SEQ ID NO: 51 or a variant thereof having at least 85% homology to SEQ ID NO: 51; and/or iii) the CD3-ζ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 52 or a variant thereof having at least 85% homology to SEQ ID NO: 52.

### Claim 88 (depends on 84, 85, 86, 87)

The method of any one of claims 84-87, wherein the anti-CTL protein comprises the amino acid sequence of SEQ ID NO: 53 or a variant thereof having at least 85% homology to SEQ ID NO: 53.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The method of any one of claims 83-88, wherein the signaling domain of the first CISC component comprises an IL-2 receptor subunit gamma (IL2Rγ) cytoplasmic signaling domain.

### Claim 90 (depends on 89)

The method of claim 89, wherein the IL2Rγ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 44 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 44.

### Claim 91 (depends on 83, 84, 85, 86, 87, 88, 89, 90)

The method of any one of claims 83-90, wherein the first extracellular binding domain or portion thereof comprises an FK506 binding protein (FKBP) domain or a portion thereof.

### Claim 92 (depends on 91)

The method of claim 91, wherein the FKBP domain comprises the amino acid sequence of SEQ ID NO: 41 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 41.

### Claim 93 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 83-92, wherein the signaling domain of the second CISC component comprises an IL-2 receptor subunit beta (IL2Rβ) cytoplasmic signaling domain.

### Claim 94 (depends on 93)

The method of claim 93, wherein the IL2Rβ cytoplasmic signaling domain comprises the amino acid sequence of SEQ ID NO: 45 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 45.

### Claim 95 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The method of any one of claims 83-94, wherein the second extracellular binding domain or portion thereof comprises an FKBP rapamycin binding (FRB) domain or a portion thereof.

### Claim 96 (depends on 95)

The method of claim 95, wherein the FRB domain comprises the amino acid sequence of SEQ ID NO: 42 or a variant thereof having at least 85% homology to the amino acid sequence of SEQ ID NO: 42.

### Claim 97 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 83-96 wherein the transmembrane domain of the first and second CISC components comprises, independently, an IL-2 receptor transmembrane domain.

### Claim 98 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 83-97 wherein the ligand is rapamycin or a rapalog.

### Claim 99 (depends on 98)

The method of claim 98, wherein the rapalog is selected from the group consisting of everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, AP21967, sodium mycophenolic acid, benidipine hydrochloride, AP1903, or AP23573, or metabolites, derivatives, and/or combinations thereof.

### Claim 100 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 83-99, wherein the c) one or more donor templates further comprise nucleic acid encoding one or more of:
iv) a selectable marker;
v) a polypeptide that confers resistance to one or more calcineurin inhibitors; or
vi) an FKBP-rapamycin binding (FRB) domain polypeptide of the mammalian target of rapamycin (mTOR) kinase.

### Claim 103 (depends on 100, 101, 102)

The method of any one of claims 100-102, wherein the selectable marker is a truncated low-affinity nerve growth factor receptor (tLNGFR) polypeptide.

### Claim 104 (depends on 103)

The method of claim 103, wherein the tLNGFR polypeptide comprises the amino acid sequence of SEQ ID NO: 54.

### Claim 105 (depends on 100, 101, 102, 103, 104)

The method of any one of claims 100-104, wherein the polypeptide that confers resistance to one or more calcineurin inhibitors is a mutant calcineurin (CN) polypeptide.

### Claim 106 (depends on 105)

The method of claim 105, wherein the mutant CN polypeptide is CNb30 (SEQ ID NO: 55).

### Claim 107 (depends on 100, 101, 102, 103, 104, 105, 106)

The method of any one of claims 100-106, wherein the FRB domain polypeptide comprises the amino acid sequence of SEQ ID NO: 56 or 57 or a variant having at least 90% sequence homology to the amino acid sequence of SEQ ID NO: 56 or 57.

### Claim 108

A method of editing the genome of a cell, the method comprising providing to the cell a first gRNA, a second gRNA, an RGEN or a nucleic acid encoding the RGEN, a first vector, and a second vector, wherein
(A) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 1 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 1, the first vector comprises the polynucleotide sequence of SEQ ID NO: 37 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 37, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 4-18, and the second vector comprises the polynucleotide sequence of SEQ ID NO: 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 40;
(B) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 2 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 2, the first vector comprises the polynucleotide sequence of SEQ ID NO: 38 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 38, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 4-18, and the second vector comprises the polynucleotide sequence of SEQ ID NO: 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 40; or
(C) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 3 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 3, the first vector comprises the polynucleotide sequence of SEQ ID NO: 39 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 39, the second gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18 and variants thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 4-18, and the second vector comprises the polynucleotide sequence of SEQ ID NO: 40 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 40.

### Claim 109

A method of editing the genome of a cell, the method comprising providing to the cell a first gRNA, an RGEN or a nucleic acid encoding the RGEN, and a first vector, wherein
(A) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 1 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 1 and the first vector comprises the polynucleotide sequence of SEQ ID NO: 19 or 22 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 19 or 22;
(B) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 2 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 2 and the first vector comprises the polynucleotide sequence of SEQ ID NO: 20 or 23 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 20 or 23; or
(C) the first gRNA comprises the polynucleotide sequence of SEQ ID NO: 3 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 3 and the first vector comprises the polynucleotide sequence of SEQ ID NO: 21 or 24 or a variant thereof having at least 85% homology to the polynucleotide sequence of SEQ ID NO: 21 or 24.

### Claim 110

A method of editing the genome of a cell, the method comprising providing to the cell a first gRNA, an RGEN or a nucleic acid encoding the RGEN, and a first vector, wherein the first gRNA comprises the polynucleotide sequence of any one of SEQ ID NOs: 4-18 or a variant thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 4-18 and the first vector comprises the polynucleotide sequence of any one of SEQ ID NOs: 25-36 or a variant thereof having at least 85% homology to the polynucleotide sequence of any one of SEQ ID NOs: 25-36.

### Claim 111 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The method of any one of claims 83-110, wherein the RGEN is selected from the group consisting of a Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cash, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cpf1 endonuclease, or a functional derivative thereof.

### Claim 112 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111)

The method of any one of claims 83-111, wherein the RGEN is Cas9.

### Claim 113 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112)

The method of any one of claims 83-112, wherein the nucleic acid encoding the RGEN is a ribonucleic acid (RNA) sequence.

### Claim 114 (depends on 113)

The method of claim 113, wherein the RNA sequence encoding the RGEN is linked to the first gRNA or the second gRNA via a covalent bond.

### Claim 115 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any one of claims 83-114, wherein the donor template is contained in an AAV vector.

### Claim 116 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The method of any one of claims 83-115, wherein the RGEN is precomplexed with the first gRNA and/or the second gRNA, forming an RNP complex, prior to the provision to the cell.

### Claim 117 (depends on 116)

The method of claim 116, wherein the RGEN is precomplexed with the first gRNA and/or the second gRNA at a molar ratio of gRNA to RGEN between 1:1 to 20:1, respectively.

### Claim 118 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The method of any one of claims 83-117, wherein the one or more donor templates are, independently, inserted into the genome of the cell.

### Claim 119 (depends on 118)

The method of claim 118, wherein a first donor template is inserted at, within, or near a TRA gene or gene regulatory element and/or a second donor template is inserted at, within, or near an IL2RG gene or gene regulatory element.

### Claim 120 (depends on 118, 119)

The method of claim 118 or 119, wherein nucleic acid encoding i) the first CISC component is inserted into an endogenous IL2RG gene, and/or nucleic acid encoding ii) the second CISC component is inserted into the region of the endogenous TIM gene encoding the TRAC domain; or nucleic acid encoding i) the first CISC component is inserted into the region of the endogenous TIM gene encoding the TRAC domain, and/or nucleic acid encoding ii) the second CISC component is inserted into the endogenous IL2RG gene.

### Claim 121 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The method of any one of claims 83-120, wherein the cell is a T cell.

### Claim 122 (depends on 121)

The method of claim 121, wherein the T cell is a CD8+ cytotoxic T lymphocyte or a CD3+ pan T cell.

### Claim 123 (depends on 121, 122)

The method of claim 121 or 122, wherein the T cell is a member of a pool of T cells derived from multiple donors.

### Claim 124 (depends on 123)

The method of claim 123, wherein the multiple donors are human donors.

### Claim 125 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The method of any one of claims 83-124, wherein the cell is cytotoxic to CTLs.

### Claim 126 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

An engineered cell produced by the method of any one of claims 83-125.

### Claim 127 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 126)

The engineered cell of any one of claims 1-39 and 126, wherein the engineered cell is cytotoxic to CTLs.

### Claim 128 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 126)

A method of treating graft vs host disease (GvHD) or an autoimmune disease in a subject in need thereof, the method comprising: administering the engineered cell of any one of claim 1-39 or 126 to the subject.

### Claim 129 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

A method of treating a disease or condition in a subject in need thereof, wherein the disease or condition is characterized by an adverse CTL-mediated immune response, the method comprising:
a) editing the genome of T cells according to the method of any one of claims 83-120, thereby producing engineered T cells; and
b) administering the engineered T cells to the subject.

### Claim 130 (depends on 129)

The method of claim 129, wherein the T cells are autologous to the subject.

### Claim 131 (depends on 120)

The method of claim 120, wherein the T cells are allogenic to the subject.

### Claim 132 (depends on 131)

The method of claim 131, wherein the T cells comprise a pool of T cells derived from multiple donors.

### Claim 133 (depends on 132)

The method of claim 132, wherein the multiple donors are human donors.

### Claim 134 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

A method of treating a disease or condition in a subject in need thereof, wherein the disease or condition is characterized by an adverse CTL-mediated immune response, the method comprising editing the genome of a T cell in the subject according to the method of any one of claims 83-120.

### Claim 135 (depends on 129, 130, 131, 132, 133, 134)

The method of any one of claims 129-134, wherein the T cells comprise CD8+ cytotoxic T cells or CD3+ pan T cells.

### Claim 136 (depends on 128, 129, 130, 131, 132, 133, 134, 135)

The method of any one of claims 128-135, wherein the subject is human.

### Claim 137 (depends on 128, 129, 130, 131, 132, 133, 134, 135, 136)

The method of any one of claims 128-136, further comprising administering rapamycin or a rapalog to the subject.

### Claim 138 (depends on 137)

The method of claim 137, wherein the rapalog is selected from the group consisting of everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, AP21967, sodium mycophenolic acid, benidipine hydrochloride, AP1903, or AP23573, or metabolites, derivatives, and/or combinations thereof.

### Claim 139 (depends on 137, 138)

The method of any one of claims 137-138, wherein the rapamycin or the rapalog is administered in a concentration from 0.05 nM to 500 nM.

### Claim 140 (depends on 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139)

The method of any one of claims 129-139, wherein the disease or condition is GvHD or an autoimmune disease.

### Claim 141 (depends on 140)

The method of claim 140, wherein the disease or condition is GvHD, and the subject has previously received an allogeneic transplant.

### Claim 142 (depends on 140)

The method of claim 140, wherein the disease is an autoimmune disease selected from the group consisting of Type 1 Diabetes (T1D), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Multiple Sclerosis (MS).

### Claim 143 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 126)

A kit comprising instructions for use and a) the engineered cell of any one of claim 1-39 or 126 and/or one or more components of the system of any one of claims 44-80; and/or b) rapamycin or a rapalog.

### Claim 144 (depends on 143)

The kit of claim 143, wherein the rapalog is selected from the group consisting of everolimus, CCI-779, C20-methallylrapamycin, C16-(S)-3-methylindolerapamycin, C16-iRap, AP21967, sodium mycophenolic acid, benidipine hydrochloride, AP1903, or AP23573, or metabolites, derivatives, and/or combinations thereof.

### Claim 145 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 126)

A syringe comprising the engineered cell of any one of claim 1-39 or 126 or a composition comprising one or more components of the system of any one of claims 44-80.

### Claim 146 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 126)

A catheter comprising the engineered cell of any one of claim 1-39 or 126 or a composition comprising one or more components of the system of any one of claims 44-80.

### Claim 147 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 126)

The use of an engineered T cell of any one of claim 1-39, 126, or 127, for the treatment of graft vs host disease (GvHD) or an autoimmune disease or a disease or condition characterized by an adverse CTL-mediated immune response.

### Claim 148 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 126)

The use of an engineered T cell of any one of claims 1-39, 126, and 127, for the manufacture of a medicament for the treatment of graft vs host disease (GvHD) or an autoimmune disease or a disease or condition characterized by an adverse CTL-mediated immune response.

### Claim 149 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The use of the system of any one of claims 44-80, for the treatment of graft vs host disease (GvHD) or an autoimmune disease or a disease or condition characterized by an adverse CTL-mediated immune response.

### Claim 150 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The use of the system of any one of claims 44-80, for the manufacture of a medicament for the treatment of graft vs host disease (GvHD) or an autoimmune disease or a disease or condition characterized by an adverse CTL-mediated immune response.

### Claim 151 (depends on 40, 41, 42, 43, 81, 82, 143, 144, 145, 146)

The use of the guide RNA of any one of claims 40-43, or the vector of claim 81 or 82, or the kit of claim 143 or 144, or the syringe of claim 145, or the catheter of claim 146, for the treatment of graft vs host disease (GvHD) or an autoimmune disease or a disease or condition characterized by an adverse CTL-mediated immune response.

### Claim 152 (depends on 40, 41, 42, 43, 81, 82, 143, 144, 145, 146)

The use of the guide RNA of any one of claims 40-43, or the vector of claim 81 or 82, or the kit of claim 143 or 144, or the syringe of claim 145, or the catheter of claim 146, for the manufacture of a medicament for the treatment of graft vs host disease (GvHD) or an autoimmune disease or a disease or condition characterized by an adverse CTL-mediated immune response.
